Skip to content

LCI- Further Improving Neoplasm Detection in upper GI

LCI- Further Improving Neoplasm Detection in upper GI - LCI-FIND TRIAL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000023863
Enrollment
1500
Registered
2016-09-30
Start date
2016-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neoplasm detection in upper GI

Interventions

Endoscopic examination with linlked color imaging before conventional white light imaging observation Endoscopic examination with linked color imaging after conventional white light imaging observati

Sponsors

National Hospital Organization Hakodate National Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who plan to undergo upper gastrointestinal endoscopy and who meet one of following 1) Patients who have history of gastrointestinal cancer (which included oral cavity, larynx, pharynx) 2) Patients whose endoscopy is performed for the present gastrointestinal cancer (which included oral cavity, larynx,pharynx) 3) Patients who have history of chemotherapy or radiotherapy 4)Patients who have history of surgical esophageal or gastric resection.

Exclusion criteria

Exclusion criteria: 1)Patients taking medicines which cause the trouble in obtaining a biopsy tissue 2)Patients who have trouble in undergoing endoscopy 3)Patients with dementia or with disctuebance of consciousness 4)Patients has determined that inappropriate by principal investigator

Design outcomes

Primary

MeasureTime frame
The primary endpoint was the percentage of patients diagnosed as having a neoplastic lesion in the pharynx, esophagus, or stomach using each of WLI and LCI in the first examination.

Secondary

MeasureTime frame
The secondary endpoints were the percentages of patients diagnosed,using WLI and LCI, as having a neoplastic lesion stratified by location,size or morphology of the lesions or diagnostic confirmation in the first examination as well as the percentage of patients diagnosed, using WLI and LCI,as having neoplastic lesions or adverse events in the second examination.

Countries

Japan

Contacts

Public ContactMotitsugu Kato

National Hospital Organization Hakodate National Hospital gastroenterology

mkato1957@gmail.com0138-51-6281

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026